Related Experiment Video
Updated: Apr 18, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis
Introduction:
Malignant hypertension (MHT) is an uncommon clinical manifestation of IgA Nephropathy (IgAN). Its prevalence, pathogenesis and evolution are not well known.
Material And Methods:
We performed a descriptive and retrospective study to report the clinical characteristics and evolution of thirteen patients diagnosed as having IgA nephropathy by renal biopsy in our hospital who developed MHT (IgAN-MHT).
Results:
The prevalence of MHT in our IgAN patients was 7% (13/186). The mean age was 37±12 years and 84% were males. Mean systolic/diastolic blood pressure at presentation were 219±32/132±18mmHg, respectively. Renal function impairment was detected at admission in all the patients, with a mean serum creatinine of 4.73±3.12mg/dL. No patient showed analytical data that suggested thrombotic microangiopathy. Renal biopsies showed mild chronicity lesions and only four patients presented features of thrombotic microangiopathy. All patients were treated with renin-angiotensin-aldosterone blockers and two received steroids. They all showed a progressive loss of renal function. At the end of follow up one patient had died, ten were on chronic dialysis and two presented chronic kidney disease stage 3b. Renal survival was 69% and 35% at 3 and 6 years, respectively. Six patients received a kidney transplant: IgAN relapsed in four patients. One of them presented a new episode of MHT associated with a HELLP syndrome.
Conclusions:
Malignant hypertension is a form of IgAN clinical presentation having a remarkably worse renal outcome and without specific effective treatment.
Insights
Malignant hypertension (MHT) is a rare IgA nephropathy (IgAN) complication. This study found IgAN-MHT significantly worsens kidney outcomes, with no specific effective treatment, highlighting a poor prognosis for affected patients.
Area of Science:
- Nephrology
- Hypertension
- Immunology
Background:
- Malignant hypertension (MHT) is an uncommon clinical manifestation of IgA Nephropathy (IgAN).
- The prevalence, pathogenesis, and evolution of MHT in IgAN are not well understood.
Purpose of the Study:
- To report the clinical characteristics and evolution of patients with IgA nephropathy and malignant hypertension (IgAN-MHT).
Main Methods:
- A descriptive and retrospective study of thirteen patients diagnosed with IgAN-MHT via renal biopsy.
- Analysis of clinical characteristics, treatment, and long-term renal outcomes.
Main Results:
- MHT prevalence in IgAN patients was 7% (13/186).
- Patients presented with severe hypertension (219/132 mmHg) and renal impairment (creatinine 4.73 mg/dL).
- All patients experienced progressive renal function loss, with high rates of dialysis (10/13) and kidney transplant relapse (4/6).
Conclusions:
- Malignant hypertension represents a severe clinical presentation of IgA Nephropathy.
- IgAN-MHT is associated with a remarkably worse renal outcome.
- No specific effective treatment currently exists for IgAN-MHT, indicating a poor prognosis.
More Related Videos
Related Concept Videos
Diabetic Nephropathy
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury II: Pathophysiology
Nephrons

